192 related articles for article (PubMed ID: 15575066)
1. Hyperkalemia and inhibitors of the renin-angiotensin-aldosterone system.
Segal A
N Engl J Med; 2004 Dec; 351(23):2450-1; author reply 2450-1. PubMed ID: 15575066
[No Abstract] [Full Text] [Related]
2. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
Weir MR; Rolfe M
Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
[TBL] [Abstract][Full Text] [Related]
3. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system.
Palmer BF
N Engl J Med; 2004 Aug; 351(6):585-92. PubMed ID: 15295051
[No Abstract] [Full Text] [Related]
4. [Old and new drugs to block aldosterone and ameliorate cardiovascular disease].
Fiebeler A; Luft FC
Dtsch Med Wochenschr; 2004 Nov; 129(46):2491-6. PubMed ID: 15536584
[No Abstract] [Full Text] [Related]
5. Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors.
Weinberg MS; Weinberg AJ; Zappe DH
J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):217-33. PubMed ID: 11881029
[No Abstract] [Full Text] [Related]
6. Increasingly restrictive definitions of hyperkalemia outcomes in a database study: effect on incidence estimates.
Raebel MA; Ross C; Cheetham C; Petersen H; Saylor G; Smith DH; Wright LA; Roblin DW; Xu S
Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):19-25. PubMed ID: 19937982
[TBL] [Abstract][Full Text] [Related]
7. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Kjeldsen SE; Julius S
Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
[TBL] [Abstract][Full Text] [Related]
8. Evolving understanding of the renin-angiotensin-aldosterone system: pathophysiology and targets for therapeutic intervention.
Gradman AH
Am Heart J; 2009 Jun; 157(6 Suppl):S1-6. PubMed ID: 19450719
[No Abstract] [Full Text] [Related]
9. [Renin-angiotensin-aldosterone system inhibitors and electrolyte disturbances].
Kato H; Kobayashi K; Uchida S
Nihon Rinsho; 2012 Sep; 70(9):1536-41. PubMed ID: 23012800
[TBL] [Abstract][Full Text] [Related]
10. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
11. What is the role of angiotensin-receptor blockade in cardiovascular protection?
Cohn JN
Am Heart J; 2006 Nov; 152(5):859.e1-8. PubMed ID: 17070145
[TBL] [Abstract][Full Text] [Related]
12. [Angiotensin receptor blocker often a valuable alternative to ACE inhibitors].
Partanen J
Duodecim; 2003; 119(13):1193-6. PubMed ID: 12908180
[No Abstract] [Full Text] [Related]
13. Tissue renin angiotensin systems: theoretical implications for the development of hyperkalemia using angiotensin-converting enzyme inhibitors.
Schlueter W; Keilani T; Batlle DC
Am J Med Sci; 1994 Feb; 307 Suppl 1():S81-6. PubMed ID: 8141171
[TBL] [Abstract][Full Text] [Related]
14. Novel imaging strategies for predicting remodeling and evolution of heart failure: targeting the Renin-Angiotensin system.
Shirani J; Narula J; Eckelman WC; Dilsizian V
Heart Fail Clin; 2006 Apr; 2(2):231-47. PubMed ID: 17386892
[No Abstract] [Full Text] [Related]
15. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if the serum creatinine and/or serum potassium concentration rises.
Palmer BF
Nephrol Dial Transplant; 2003 Oct; 18(10):1973-5. PubMed ID: 13679467
[No Abstract] [Full Text] [Related]
16. Mechanisms of disease: local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular disease.
Re RN
Nat Clin Pract Cardiovasc Med; 2004 Nov; 1(1):42-7. PubMed ID: 16265259
[TBL] [Abstract][Full Text] [Related]
17. Hyperkalemia risk and treatment of heart failure.
Segura J; Ruilope LM
Heart Fail Clin; 2008 Oct; 4(4):455-64. PubMed ID: 18760757
[TBL] [Abstract][Full Text] [Related]
18. [Atrial fibrillation: potential therapeutic interventions in the renin-angiotensin-aldosterone system].
Dabrowski R; Szwed H
Kardiol Pol; 2007 Apr; 65(4):440-5. PubMed ID: 17530565
[No Abstract] [Full Text] [Related]
19. [Pathophysiology of the renin-angiotensin-system in atrial fibrillation].
Heusch G; Schulz R
Dtsch Med Wochenschr; 2006 Apr; 131(15):817-20. PubMed ID: 16607602
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic possibilities for the inhibition of the renin-angiotensin-aldosterone system].
Abrahám G; Légrády P
Orv Hetil; 2003 May; 144(18 Suppl 1):892-5. PubMed ID: 12785232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
